– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
– The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended…
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a…
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary…
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and…
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today…
100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants…
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today…
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…